Detalhe da pesquisa
1.
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020.
Clin Infect Dis
; 78(5): 1352-1359, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38366649
2.
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep
; 73(9): 209-214, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457312
3.
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
MMWR Morb Mortal Wkly Rep
; 73(8): 168-174, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421935